Charles Schwab Investment Management Inc. Has $3.65 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Charles Schwab Investment Management Inc. increased its ownership of Kiniksa Pharmaceuticals International by 34.7%, acquiring an additional 42,353 shares in the first quarter, bringing its total to 164,372 shares worth approximately $3.65 million.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, exceeding analyst expectations of $0.18, with quarterly revenue of $156.80 million.
• Several analysts downgraded Kiniksa's stock rating, with Wall Street Zen lowering it to a "buy," while Jefferies Financial Group raised its price target to $54.00, indicating mixed investor sentiment.

Charles Schwab Investment Management Inc. boosted its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 34.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 164,372 shares of the company's stock after purchasing an additional 42,353 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.23% of Kiniksa Pharmaceuticals International worth $3,651,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of KNSA. Wells Fargo & Company MN lifted its position in Kiniksa Pharmaceuticals International by 54.7% in the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after purchasing an additional 7,463 shares during the last quarter. Barclays PLC lifted its position in Kiniksa Pharmaceuticals International by 11.2% in the 4th quarter. Barclays PLC now owns 71,896 shares of the company's stock valued at $1,423,000 after purchasing an additional 7,267 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Kiniksa Pharmaceuticals International by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares during the last quarter. MetLife Investment Management LLC lifted its position in Kiniksa Pharmaceuticals International by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after purchasing an additional 1,374 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Kiniksa Pharmaceuticals International by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after purchasing an additional 4,575 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded down $0.28 on Thursday, reaching $35.21. 40,067 shares of the company were exchanged, compared to its average volume of 671,154. The firm has a market capitalization of $2.61 billion, a PE ratio of 880.35 and a beta of 0.20. The stock's fifty day moving average price is $30.65 and its 200 day moving average price is $26.27. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $35.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 11,000 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total transaction of $383,240.00. Following the transaction, the chief accounting officer owned 38,011 shares in the company, valued at $1,324,303.24. This represents a 22.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Malley sold 78,233 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the transaction, the director owned 12,546 shares in the company, valued at approximately $415,147.14. The trade was a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 558,403 shares of company stock worth $18,078,671 in the last quarter. 53.48% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KNSA. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 30th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.